NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...
Raymond James engaged as financial advisor Reduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing ...
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, ...
IO Biotech, Inc. (NASDAQ:IOBT) is one of the 11 Low Price High Volume Stocks to Buy According to Analysts. On August 15, H.C. Wainwright reiterated a Buy rating on IO Biotech, Inc. (NASDAQ:IOBT), ...
Zacks Investment Research on MSN
Here's why IO Biotech, Inc. (IOBT) looks ripe for bottom fishing
Shares of IO Biotech, Inc. (IOBT) have been struggling lately and have lost 31.1% over the past four weeks. However, a hammer chart pattern was formed in its last trading session, which could mean ...
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...
NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the transformative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results